The deal covers SpeeDx's PlexPCR and ResistancePlus multiplex real-time PCR diagnostic products in certain European nations.
The investment bank took note of Danaher's soft organic growth rate in the first quarter, and said it will need to build up its life science portfolio.
The test, which detects DNA methylation markers, is being developed as an alternative to invasive cystoscopy, the current standard of care.
The company has also developed software that will enable automated melt curve analysis on Cepheid's existing GeneXpert platforms.
The tests are twice as fast as the firm's Xpert line and run on Cepheid's flagship GeneXpert system.
Overall growth was driven by the company's diagnostics segment, which rose 11 percent, while life sciences improved 6 percent
Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.
To develop the test, the firm said it used a library of MRSA strains collected around the world, and included components that reduce false positive results.
The evidence-based guidelines for testing individuals at risk of latent or active TB infection include recommendations on interferon-gamma release and molecular assays.
Cepheid noted that the cartridge is not currently part of its five-year commercial plan, but the firm is in discussions with outside parties to push development forward.
Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.
Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.
Slate's Jane Hu compares some at-home genetic tests to astrology.
In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.